Anzeige
Mehr »
Samstag, 23.05.2026 - Börsentäglich über 12.000 News
Am 24. Mai wird es explosiv: +40% Kursgewinn in 5 Tagen: Eskaliert diese Nasdaq-Aktie jetzt komplett?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0CBDJ | ISIN: KYG8167W1380 | Ticker-Symbol: SMZ1
Tradegate
22.05.26 | 17:58
0,565 Euro
-1,70 % -0,010
Branche
Biotechnologie
Aktienmarkt
HANG SENG
1-Jahres-Chart
SINO BIOPHARMACEUTICAL LTD Chart 1 Jahr
5-Tage-Chart
SINO BIOPHARMACEUTICAL LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,5650,58322.05.
0,5640,58622.05.

Aktuelle News zur SINO BIOPHARM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrSBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - DATA FROM TWO CLINICAL STUDIES OF M701 "CD3/EPCAM BISPECIFIC ANTIBODY" PRESENTED AT 2026 ASCO4
DoSBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - ZONGERTINIB, A HER2 TYROSINE KINASE INHIBITOR, APPROVED FOR FIRST-LINE TREATMENT OF HER2-MUTANT NON-SMALL ...8
SINO BIOPHARM Aktie jetzt für 0€ handeln
15.05.SBP GROUP (01177): NEXT DAY DISCLOSURE RETURN1
14.05.SBP GROUP Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity5
14.05.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH DATA ON TQF6422 "ACTRII A/B MONOCLONAL ANTIBODY" PRESENTED AT ECO 20263
12.05.GSK and SBP Group team up to advance bepirovirsen launch in China3
12.05.G Sachs Raises SBP GROUP TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug6
11.05.GSK strikes agreement with China's SBP Group, launches final tranche of buyback programme4
11.05.SBP GROUP Forms Exclusive Strategic Partnership with GlaxoSmithKline to Accelerate Mainland Launch of bepirovirsen4
11.05.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE STRATEGIC COLLABORATION WITH GSK4
07.05.SBP GROUP (01177): NEXT DAY DISCLOSURE RETURN1
07.05.SBP GROUP's Category 1 Innovative Drug M701 NDA Accepted3
07.05.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR M701 "CD3/EPCAM BISPECIFIC ANTIBODY"2
07.05.SBP GROUP CCR8 Monoclonal Antibody for Gastric Cancer Completes First Patient Enrollment in Clinical Trial4
07.05.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF CAFELKIBART "CCR8 MONOCLONAL ANTIBODY" ...2
06.05.SBP GROUP: Kumoxili Capsules Approved in Mainland for 2nd Indication7
06.05.SBP GROUP (01177): VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF CULMERCICLIB CAPSULE "CDK2/4/6 INHIBITOR" FOR FIRST-LINE TREATMENT OF BREAST CANCER APPROVED ...2
30.04.SBP GROUP (01177): NEXT DAY DISCLOSURE RETURN2
29.04.SBP GROUP (01177): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT4
29.04.SBP GROUP (01177): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS3
Weiter >>
82 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1